CDRI planning to launch Phase-1 trials on 2 candidate drugs to fight malaria, diabetes « New Drug Approvals

CDRI planning to launch Phase-1 trials on 2 candidate drugs to fight malaria, diabetes « New Drug Approvals:



'via Blog this'

Elbasvir, MK 8742 ……….Anti-Hepatitis C Virus Drug in phase 2 « New Drug Approvals

Elbasvir, MK 8742 ……….Anti-Hepatitis C Virus Drug in phase 2 « New Drug Approvals:



'via Blog this'

Ambit Biosciences announces Phase 3 trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation. « New Drug Approvals

Ambit Biosciences announces Phase 3 trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation. « New Drug Approvals: "dIn"



'via Blog this'

NERATINIB, HKI 272, ..Puma presents positive results from phase II trial of its investigational drug PB272 « New Drug Approvals

NERATINIB, HKI 272, ..Puma presents positive results from phase II trial of its investigational drug PB272 « New Drug Approvals:



'via Blog this'

Doravirine, MK-1439 reverse transcriptase inhibitor In Phase 3 for treatment of HIV-1 infection « New Drug Approvals

Doravirine, MK-1439 reverse transcriptase inhibitor In Phase 3 for treatment of HIV-1 infection « New Drug Approvals:



'via Blog this'

Cabotegravir, GSK 744 IN PHASE 2 FOR HIV INFECTION « New Drug Approvals

Cabotegravir, GSK 744 IN PHASE 2 FOR HIV INFECTION « New Drug Approvals: "

Cabotegravir, GSK 744,

(3S,11aR)-N-(2,4-Difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide

3S, 1 1 aR)- N-[(2,4-difluorophenyl)methyl]-2,3,5,7, 1 1 , 1 1 a-hexahydro-6-hydroxy-3- methyl-5,7- dioxo-oxazolo[3,2-a]pyrido[1 ,2-d]pyrazine-8-carboxamide"



'via Blog this'

Cabotegravir, GSK 744 IN PHASE 2 FOR HIV INFECTION « New Drug Approvals

Cabotegravir, GSK 744 IN PHASE 2 FOR HIV INFECTION « New Drug Approvals: "

Cabotegravir, GSK 744,

(3S,11aR)-N-(2,4-Difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide

3S, 1 1 aR)- N-[(2,4-difluorophenyl)methyl]-2,3,5,7, 1 1 , 1 1 a-hexahydro-6-hydroxy-3- methyl-5,7- dioxo-oxazolo[3,2-a]pyrido[1 ,2-d]pyrazine-8-carboxamide"



'via Blog this'